Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Licenses Gene Group IP from Kimmel Cancer Center

NEW YORK, April 15 (GenomeWeb News) - Stratagene today announced that it has exclusively licensed intellectual property held by the Sidney Kimmel Cancer Center of San Diego.

 

Under the terms of the agreement, Stratagene will get access to pending patents and related technology developed in the lab of Gennadi Glinsky and used to discover cancer-related genes. Stratagene will obtain exclusive rights to certain gene groups that have been shown to have predictive capabilities for cancer, particularly prostate, and breast cancers.

 

Financial terms of the agreement were not disclosed.

 

The company said it would use the IP to develop diagnostic tests based on its quantitative PCR technology.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.